TiumBio Co., Ltd.

TiumBio Co., Ltd.

KKRX:321550
3,345.00
KRW
-35.00
(-1.04%)
-640.51EPS
121.58BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.72
114.27
55.56
44.66
2.39
380.55
200.75
262.89
453.03
521.95
Basic EPS, GAAP
-379.25
-1,392
-354
-516
-1,329
-1,246
-734
-799
-640
-595.54
Free Cash Flow per Basic Share
-304.76
-535.2
-250.72
-437.46
-1,541.32
-1,140.86
-1,597.31
-645.31
-578.24
-547.46
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-306.51
1,243.73
3,942.84
3,469.01
3,632.69
2,513.07
2,746.48
1,914.6
1,348.04
1,188.19
Tangible Book Value per Share
-422.23
1,138.78
3,854.54
3,397.32
3,577.35
2,468.43
2,723.05
1,849.11
1,284.46
1,123.91
Basic Weighted Avg Shares
23
10
20
23
24
24
24
26
27
29
Sales/Revenue/Turnover
226
1,129
1,113
1,049
57
9,118
4,899
6,792
12,289
14,997
Operating Margin (%)
-1,881.76
-464.26
-720.54
-1,268.26
-57,566.15
-281.22
-568.14
-275.3
-131.33
-107.24
Depreciation Expense
287
561
834
1,018
1,944
3,472
3,254
3,799
3,677
3,544
Net Income, GAAP
-8,795
-13,752
-7,091
-12,119
-31,637
-29,853
-17,911
-20,644
-17,360
-17,111
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-3,900.17
-1,218.14
-637.15
-1,155.33
-55,701.69
-327.42
-365.62
-303.93
-141.27
-114.1
Working Capital
6,148
25,354
89,479
68,075
37,434
10,185
21,491
19,574
4,955
-3,197
LT Debt
- -
- -
- -
931
18,624
3,561
23,235
16,680
14,384
10,774
Total Equity
-7,085
28,749
92,498
82,507
90,319
62,287
70,374
50,760
37,744
32,519
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-11.7
-13.85
-37.35
-40.55
-27.79
-34.5
-38.25
-44.06

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
17,769
17,297
17,788
LT Borrowings
13,400
12,650
10,500
LT Finance Leases
984
771
274
Preferred Equity and Hybrid Capital
1,164
1,164
1,164
Shares Outstanding
29
29
29
Market Capitalization
176,121
350,184
121,579

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
50,909
47,846
44,063
Cash, Cash Equivalents & STI
42,391
37,482
32,800
Accounts Receivable, Net
1,596
1,480
1,363
Inventories
324
414
505
Total Current Liabilities
45,954
47,534
47,259
Payables & Accruals
- -
- -
- -
ST Debt
17,769
17,297
17,788
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-12.42%
-25.64%
Free Cash Flow
- -
42.22%
-5.92%
Net Income, GAAP
- -
22.96%
-15.9%
Sales/Revenue/Turnover
- -
3,186.29%
80.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,992
2,186
1,132
1,482
6,792
2025
2,106
2,613
3,121
4,448
12,289
2026
2,950
4,477
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-294
-491
-159
137.11
-799
2025
-296
-76
-203
-67.84
-640
2026
-185.98
-143
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Hoon-Taek Kim
Full Time Employees
67
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Seongnam-si South Korea
IPO Date
Dec 22, 2019
Business
TiumBio Co., Ltd. is a South Korea-based clinical-stage biopharmaceutical company that engages in the discovery, research, and development of innovative small-molecule and biological therapeutics for rare, incurable, and underserved medical conditions. Founded in 2016 and headquartered in Seongnam, South Korea, the company specializes in therapeutics targeting immuno-oncology, gynecology, fibrosis, and hematological disorders. TiumBio operates through its core drug discovery platforms and biopharmaceutical service units, offering a pipeline of investigational assets and contract services that includes Merigolix (TU2670), an orally active, once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of endometriosis, uterine fibroids, and assisted reproductive technology; Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta receptor 1 (TGF-beta R1) and vascular endothelial growth factor receptor 2 (VEGFR2) designed to modulate the tumor microenvironment in solid tumors such as head and neck squamous cell carcinoma, biliary tract cancer, and colorectal cancer; TU7710, a recombinant activated factor VII (rFVIIa) utilizing transferrin-fusion technology engineered as a long-acting bypassing agent for hemophilia A and B patients who have developed neutralizing inhibitors; discovery-stage programs focused on pulmonary fibrosis, non-alcoholic steatohepatitis, and autoimmune diseases; and specialized Chemistry, Manufacturing, and Controls (CMC) development, process optimization, and analytical testing services delivered through its biopharmaceutical Contract Development and Analysis Organization (CDAO) subsidiary, Protium Science Co., Ltd. The company also maintains a research subsidiary, Initium Therapeutics, located in Boston, Massachusetts, to develop antibody-based therapies. In recent operational and strategic developments, TiumBio has advanced several lead candidates through international clinical partnerships and licensing transactions, including an exclusive development and commercialization agreement with Hansoh Pharmaceutical Group Co., Ltd. for Merigolix in Greater China; a clinical collaboration and supply agreement with Merck & Co., Inc. (MSD) to evaluate Tosposertib in combination with pembrolizumab (Keytruda) in Phase 2 clinical trials; and a co-development partnership with Daewon Pharmaceutical Co., Ltd. for domestic clinical trials in uterine fibroids. Furthermore, the company has completed Phase 2 clinical testing for Merigolix in uterine fibroids, advanced TU7710 into Phase 1b clinical trials, reported interim Phase 2a response data for Tosposertib in recurrent or metastatic solid tumors, and implemented strategic capital reallocations and private financings to accelerate its clinical-stage pipeline toward global licensing opportunities.